Pharmaceutical major Wockhardt Ltd said on Monday it has received USFDA approval for marketing the antibiotic Ceftriaxone Sodium injection in the US.
The company's US subsidiary, Wockhardt USA Inc is expected to launch the antibiotic, which belongs to a group of drugs called cephalosporins, in the next few weeks.
Ceftriaxone Sodium is the generic version of Hoffman La Roche's Rocephin injection.
"The approval marks Wockhardt's entry into the US injectables market. This is the first out of nine injectables that we have filed with the USFDA. We expect to launch several more products including injectables in the US this year," the company's chairman Habil Khorakiwala said.
With this approval, the company now has 12 products in the US market compared to five last year. It also has over 20 products awaiting USFDA approval, Wockhardt informed the stock exchanges.
Ceftriaxone is manufactured at the facility in Ankleshwar and the formulation is manufactured at the cephalosporin formulation plant at Waluj in Aurangabad, which was recently approved by USFDA.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group